TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Roivant Sciences Ltd. has a 12 month low of $8.47 and a 12 month high of $13.06. The company has a market capitalization of $8.53 billion, a P/E ratio of 2.07 and a beta of 1.24.

Strive Enterprises, a financial services company co-founded by former Republican presidential candidate Vivek Ramaswamy, has announced plans to move its headquarters to Dallas.

This page features the latest news about the Roivant Sciences stock. Roivant Sciences Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback Roivant (Nasdaq ...

Vivek Ramaswamy (American entrepreneur who founded Roivant Sciences) will also be very influential and will surely support ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Check the time stamp on this data. Updated AI-Generated Signals for Roivant Sciences Ltd. (ROIV) available here: ROIV.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting ...